As part of the preparations for launching its innovative NeoNavia biopsy system in the US market, the medical technology company NeoDynamics has started a subsidiary in the USA, NeoDynamics USA Inc.
The subsidiary makes it easier for NeoDynamics to recruit and hire employees, and enter into various types of agreements which will directly support the launch. Currently, NeoDynamics has Anna Forsberg operating locally in the US to lead the activities required to register the product with the US Food and Drug Administration. Business Development Manager Magnus Precht explains the investment in the USA in an interview which can be reached at the following link: https://www.youtube.com/watch?v=SO_rpFRR-us
“The introduction of NeoNavia in the US needs to be prepared, which is why we are now gradually increasing our activities in the US market. Establishing a subsidiary in this large market is an important milestone for us,” says CEO Anna Eriksrud.
At the end of February, the company submitted a registration application for NeoNavia to the US Food and Drug Administration.
For further information, please contact:
Anna Eriksrud, CEO NeoDynamics AB, phone +46708 444 966 or e-mail email@example.com
NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of breast cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at leading clinics in UK, Germany, and Sweden. The pulse biopsy system has been used for tissue sampling in breast and axilla in over 500 patients.
NeoNavia is a modern biopsy system with a completely new patented pulse technology intended for ultrasound-guided tissue sampling. It consists of a base unit, a handheld driver and three different types of biopsy needles. Each needle type is driven by the pulse technology providing a more controlled needle insertion and precise placement of the needle in the tumour whilst enabling high-quality tissue samples from both breasts and lymph nodes. The pulse biopsy system NeoNavia is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment.